CKD Staging by eGFR (KDIGO 2012)
Classifies CKD stage by eGFR and albuminuria category (G1-G5, A1-A3) per KDIGO 2012 guidelines.
Score interpretation
G1-G2/A1. Low risk. eGFR normal or mildly reduced, no or minimal albuminuria.
→ Annual monitoring. Identify and treat reversible causes. Lifestyle modifications. Blood pressure <130/80 mmHg.
Moderate risk. G3a/A1 or G1-G2/A2.
→ 6-monthly monitoring of eGFR and UACR. ACEi/ARB if proteinuria and diabetes/hypertension. Minimise nephrotoxins.
High risk. G3b or A2 with low eGFR.
→ 3-monthly monitoring. Nephrology review. Anaemia and bone disease assessment. Avoid NSAIDs and contrast agents.
Very high risk. G4-G5 or A3.
→ Nephrology specialist care. CKD education (dialysis options, transplant). Prepare for renal replacement therapy. Monthly monitoring.
Interpretation bands for the CKD Stage. Apply clinical judgement and local guidance.
References
- KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl. 2013;3(1):1-150.
Related
Curated clinical cross-links plus same-class fallbacks.
- AIR Score for Appendicitis · Diagnostic
- Spontaneous Bacterial Peritonitis (SBP) Diagnosis · Diagnostic
- Modified Alvarado Score (MANTRELS) for Appendicitis · Diagnostic
- New Orleans Head CT Decision Rule · Diagnostic
- MS Phenotype Classification (McDonald / Phenotype) · Diagnostic
- CHALICE Rule for Childhood Head Injury · Diagnostic
- Cetuximab · Anti-EGFR Monoclonal Antibody — Head and Neck Cancer
- Fluorescein Sodium 2% Eye Drops · Diagnostic ophthalmic dye
- Indocyanine Green (Intravitreal Chromovitrectomy) · Diagnostic Dye — Vitreoretinal Surgery / ICG Angiography
- Fluorescein sodium · Ophthalmic diagnostic dye
- Fluorescein with lidocaine · Topical anaesthetic + diagnostic dye
- Cetuximab (Specialist drug) · Anti-EGFR monoclonal antibody
- Hyperkalaemia Management · UK Kidney Association Guidelines 2020; NICE CKD Guidelines
- Rhabdomyolysis · Renal Association 2018; UpToDate 2024
- Hypocalcaemia (Adult) · Society for Endocrinology
- SIADH (Endocrine Perspective) · European Hyponatraemia Guidelines 2014
- Hepatorenal Syndrome · EASL 2018; ICA 2015
- Acute Kidney Injury (AKI) · KDIGO 2012 / NICE AKI 2019
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.